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WHAT THIS PAPER ADDS
 Our work demonstrates that simvastatin exerts profound effects on free radical formation in aortic aneurysms. We propose nuclear
factor-kappaB (NF-kB) being involved in the signalling events. To the best of our knowledge, our report shows the ﬁrst human data
in this special ﬁeld.a r t i c l e i n f o
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Objectives: Statins have been reported to suppress the progression of abdominal aortic aneurysm (AAA).
However, the effects of statins on inﬂammatory processes and free radicals generation are poorly
understood.
Methods: Wall samples from 51 patients (simvastatin patients, n ¼ 34; non-statin patients, n ¼ 17;
matched by sex, age and aneurysm size) subjected to elective open AAA repair were analysed. We
examined the effects of simvastatin on lipid peroxidation (4-hydroxy-trans-2-nonenal (4-HNE)),
hydrogen peroxide (H2O2), tumour necrosis factor alpha (TNF-a) concentration, superoxide dismutase
(SOD) and catalase (CAT) activity as well as nuclear factor kappa B (NF-kB) pathway activation in human
AAA wall samples.
Results: Treatment with simvastatin resulted in a decrease in 4-HNE and TNF-a concentration (median
4.18 mg/mg protein vs. 4.75, p ¼ 0.012; median 10.33 pg/ml vs. 11.81, p ¼ 0.026, respectively). CAT activity
was higher in the simvastatin group (median 3.98 U ml vs. 3.19, p ¼ 0.023). NF-kB expression was lower
(p ¼ 0.018) in the simvastatin group. However, simvastatin had little effect on H2O2 concentration
(p ¼ 0.832) and SOD activity (p ¼ 0.401).
Conclusion: Simvastatin inhibits free radicals and TNF-a generation and improves antioxidant capacity of
human AAA wall tissue, possibly through the suppression of NF-kB activity. This may be one possible
explanation how statins can inhibit AAA oxidative stress.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The abdominal aortic aneurysm (AAA) causes 1e2% of all male
deaths over the age of 65 in western countries.1 As opposed to the
occlusive form of atherosclerosis, aneurysm may be considered asGeneral Surgery, Division of
hringer Guertel 18-20, 1090
(M. Klinger).
ciety for Vascular Surgery. Publishea dilatative form of atherosclerosis.2 In atherosclerotic plaques
excessive recruitment of monocytes, macrophages, T cells, B cells
and natural killer (NK) cells is observed.3 Their activation leads to
secretion of humoral inﬂammatory factors and reactive oxygen
species (ROS).
ROS play a crucial role in the genesis of vascular pathologies and
lipid peroxidation.4 It has been shown that human aneurysmal
aorta is characterised by increased oxidative damage and pro-d by Elsevier Ltd. All rights reserved.
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intracellular signalling pathways such as c-Jun N-terminal kinase
(JNK) or nuclear factor kappa B (NF-kB).6 NF-kB is a redox-sensitive
transcription factor activated by the ROS in arterial diseases.7
Moreover, activation of NF-kB can be elicited by a wide range of
stimuli, including vascular injury, cytokines and bacterial endo-
toxines.8,9 Normally, NF-kB is kept inactive in the cytoplasm by
binding to inhibitory proteins, namely, the IkB family. Upon acti-
vation, phosphorylated NF-kB translocates to the nucleus, where it
leads to the transcription of proinﬂammatory genes.10 Inhibition of
NF-kB, at least in part, could counteract the toxic effects of ROS.
Statins, beyond their effect on lipid proﬁle, also exert pleiotropic
effects on endothelial function, vascular inﬂammation and immu-
nomodulation.11,12 One of the commonly used statins is simvastatin.
It decreases tumour necrosis factor alpha (TNF-a) serum level and
suppresses aneurysm expansion in adult rats, as well as reducing
matrix metalloproteinases 9 (MMP-9) and NF-kB levels, when used
in animal models of hypercholesterolaemia.13e15 Simvastatin
decreases levels of different interleukins (IL-4, -5, -6, -8 and -10),
interferon gamma (INF-g), TNF-b andMMP-8 in AAA. It also inhibits
T lymphocytes and macrophages recruitment in the AAA walls.16
However, the effects of simvastatin on ROS concentration in AAA
tissues have not been characterised yet. Therefore, we have here
compared human AAA tissue samples from patients, treated with
or without simvastatin, to determine whether simvastatin treat-
ment inﬂuences oxidative stress and antioxidant properties of
human AAAwall tissue. Moreover, wewanted to verify whether the
NF-kB pathway in human AAA wall may be inﬂuenced by simvas-
tatin treatment.
Material and Methods
Patients
Between September 2009 and November 2011, 98 patients
underwent elective open AAA repair at our institution. Exclusion
criteria for our study were the intake of statins other than sim-
vastatin, chronic diseases such as liver disease, malignant disease,
drug intake or alcohol abuse. Of the patients eligible for our study,
only 17 patients received no statin therapy (14 men and three
women). Following a written informed consent, patient data were
prospectively entered into a database. Subsequently, the aneu-
rysm wall tissues were harvested during aneurysm repair
procedures, to be used in retrospective analysis. Patients were
matched in a 2 (simvastatin) to 1 (non-statin) ratio, respectively,
by age, gender and AAA diameter. Accordingly, 34 patients who
received simvastatin (29 men and ﬁve women) in their medical
history (20e40 mg daily dosage) for a minimum of 6 months
were included in the study as the simvastatin group. For one 2:1
match with a female non-statin patient, only one comparable
female patient within the simvastatin group was available; and
a male simvastatin patient was matched instead. The AAA diam-
eter was determined with preoperative computed tomography
angiography (CTA).
Coronary artery disease (CAD)was deﬁned by a history of angina
pectoris or myocardial infarction. Cerebrovascular disease (CVAD)
is deﬁned by a history of transient ischaemic attack, stroke, carotid
artery stenting or surgery, respectively. Patients with asymptomatic
high grade (>85%) carotid stenosis, diagnosed by duplex sonog-
raphy or CTA were subjected to carotid artery surgery prior to
aneurysm repair (one patient in each group). Heart insufﬁciency
was deﬁned by a global ejection fraction of <50% in echocardiog-
raphy. Peripheral artery disease was deﬁned by symptomatic
claudication and a corresponding ﬁnding in the CTA at the level of
the iliac and/or femoro-popliteal vessels.Hypertension was deﬁned by the intake of antihypertensives
and/or a repeatedly elevated blood pressure exceeding 140 over
90 mmHg. Type 2 diabetes was deﬁned by the intake of antidia-
betics or requirement of insulin and/or insulin resistance. Nicotine
(y/n) pertains to nicotine consumption within the last 3 years.
The study was approved by the local research Ethics Committee
(EC 294/2009).
Tissue harvesting
The aorta was approached transperitoneally. After aortic
clamping and longitudinal incision of the aneurysm, thrombus
(present in 82 of 98 patients) was removed and about 3 cm2 of the
aneurysm sack at the site of its maximum diameter were excised.
Aneurysm samples were immediately frozen in liquid nitrogen and
stored at 80 C. For subsequent analysis, aneurysm tissue was
processed on ice. Aneurysmwall was divided into 50mg pieces and
rinsed with ice-cold saline to eliminate liquid components, such as
blood and residual thrombi.
Lipid peroxidation level measured as 4-hydroxy-trans-2-nonenal
(4-HNE) level
We measured concentrations of 4-HNE, a natural bi-product of
lipid peroxidation, using an enzyme-linked immunosorbent assay
(ELISA) kit (Cell Biolabs, San Diego, CA, USA). Brieﬂy, sample or
standard 4-HNE protein adducts were probed with the primary
antibody, followed by horseradish peroxidase (HRP)-conjugated
secondary antibody. The absorption was read at 450 nm (Perkin
Elmer, Victor 3 reader, MA, USA). Values were expressed as mg/mg
of protein. Assays were performed twice with three different tissue
scraps.
Hydrogen peroxide measurement
Tissue samples were homogenised in 1.15% KCl using a tissue
raptor (IKA Werke GmbH & Co. KG, Germany). Next, a mixture of
phosphate-buffered saline (PBS) (pH 7.0) and HRP (1 U/ml; HRP)
containing 400 mM homovanilic acid (HVA) was added to assay
HRP HVA, while PBS and 1 U/ml HRP was added to the other tube
to assay HRP. After 60 min of incubation in 37 C, PBS and 0.1 M
glycineeNaOH buffer (pH 12.0) with 25 mM ethylenediamine tetra
acetic acid (EDTA) were added to stop the enzymatic reaction.
Fluorescence was measured at excitation wave (312 nm) and
emission wave (420 nm) using a ﬂuorescence spectrophotometer
F4500 (Hitachi, JPN). Readings were converted into hydrogen
peroxide (H2O2) concentration (mmol/mg protein) using the
regression equation and normalised to aortic weight. Assays were
performed twice with three different tissue scraps.
Measurement of catalase and superoxide dismutase activity
Frozen aortic wall sample was homogenised and tissue catalase
(CAT) or superoxide dismutase (SOD) activity was measured spec-
trophotometrically using respective assay kits (Cayman Chemical,
NC, USA) following the manufacturer’s instruction. The absorption
was read at 540 nm for CAT and at 450 nm for SOD assay (Perkin
Elmer, Victor 3 reader, MA, USA). Values were expressed as pg/ml
and normalised to total protein. Assays were performed twice with
three different tissue scraps.
Immunoenzymatic assay of TNF-a concentration
Fifty milligrams of frozen aortic wall was gridded in HEPES
buffer (20 mM HEPES (pH 7.6), 1.5 mM EDTA, 0.5 mM benzamidine
Table 1
Patient demographics. Data are presented as frequencies or median
(minimumemaximum).
Parameter Non-statin
patients
(n ¼ 17)
Simvastatin
patients
(n ¼ 34)
p
Age (years), median (range) 69.83 (50.3e75.3) 67.29 (55.6e80.3) 0.786
Sex (male) 14 (82%) 29 (85%) 0.793
AAA diameter (r) (mm) 55 (48e120) 55 (48e120) 0.102
Body mass index, mean (range) 27.2 (23e37.6) 26.0 (22e34.5) 0.282
Cholesterol [mg/dl],
median (range)
238 (143e323) 203.5 (110e300) 0.017
LDL [mg/dl], median (range) 144 (60e218) 117 (56e218) 0.057
HDL [mg/dl], median (range) 46.0 (20e68) 48.0 (29e75) 0.514
Coronary artery disease 3 (18%) 8 (23%) 0.647
Cerebrovascular artery disease 0 (0%) 2 (6%) 0.547
Peripheral artery disease 3 (18%) 12 (35%) 0.123
Heart insufﬁciency 2 (12%) 7 (21%) 0.491
Hypertension 15 (88%) 31 (91%) 0.754
Type 2 diabetes 3 (18%) 7 (21%) 0.822
Nicotine 12 (70%) 24 (70%) 1.000
CRP [mg/dl], median (range) 0.42 (0.03e3.0) 0.40 (0.06e9.45) 0.946
Fibrinogen [mg/dl],
median (range)
384 (260e557) 364.5 (213e650) 0.733
Leucocytes [mln/ml],
median (range)
8.05 (5.5e11.6) 8.0 (5.09e13.0) 0.642
Creatinine [mg/dl],
median (range)
1.21 (0.77e1.48) 1.05 (0.76e4.0) 0.638a
Statistical signiﬁcance for binary variables was assessed using generalized linear
models, while metric values were analysed using linear mixed regression models.
a An extreme outlier of 4.0 was deleted in simvastatin group for p-value
comparison.
Table 2
The inﬂuence of simvastatin on oxidative stress parameters (lipid peroxidation and
hydrogen peroxide level), antioxidant power (antioxidant enzymes activity) and
TNF-a concentration in human AAA wall homogenates (median (minemax)).
Non-statin (n ¼ 17) Simvastatin (n ¼ 34) p
4-HNE (mg/mg protein) 4.75 (2.91e17.16)b 4.18 (1.21e7.83)b 0.012
H2O2 (mmol/mg protein) 0.16 (0.03e1.89) 0.23 (0.04e1.01) 0.832
SOD activity (U/ml) 0.17 (0.14e0.26) 0.18 (0.14e0.55) 0.650a
CAT activity (nmol/min/ml) 3.19 (1.29e5.34) 3.98 (1.62e7.10) 0.023
TNF-a (pg/ml) 11.81 (7.53e19.75) 10.33 (8.39e13.68) 0.026
4-HNH e 4-hydroxy-trans-2-nonenal; H2O2 e hydrogen peroxide; SOD e super-
oxide dismutase; CAT e catalase.
a An extreme outlier of 0.55 was deleted in simvastatin group for p-value
comparison.
b n ¼ 14 and n ¼ 30 in the non-statin and the simvastatin group, respectively.
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20 min), the supernatant was diluted and the TNF-a levels were
quantiﬁed according to the manufacturer’s instructions using
speciﬁc ELISA kits (Quantikine TNF-a, R&D Systems, MN, USA). The
absorption was read at 450 nm (ELx800 Bio-Tech Instruments
Reader, VT, USA). Values were expressed as pg/ml and normalised
to total protein. Assays were performed twice, with three different
tissue scraps.
Western blot analyses of p65 and phosphorylated p65 (pp65)
Equal protein amounts of nuclear extracts were separated by
sodium dodecyl sulphateepolyacrylamide gel electrophoresis
(SDSePAGE), and p65 and pp65 were assessed by Western blotting
using the anti-rabbit p65 or pp65 antibody (Santa Cruz Biotech-
nology, CA, USA and Cell Signaling, MA, USA, respectively). Signal
intensity was quantiﬁed using an ImagineMaster VDS (Bio-Rad, CA,
USA) and normalised to b-tubulin. Assays were performed twice
with different tissue scraps.
Statistical analysis
Continuous demographic and biochemical data are presented as
median, minimum and maximum, demographic categorical data
are described with absolute frequencies and percentages. Data are
2:1 matched in non-statin and simvastatin groups. A generalised
linear model (binomial, logit) with an exchangeable correlation
matrix was used to analyse matched binary outcome data. A linear
mixed model with a compound symmetry varianceecovariance
matrix was used to analyse matched continuous outcome data. In
case of skew residuals, a logarithmic transformation usually led to
normally distributed errors. Only in two variables (creatinine and
SOD), it was necessary to exclude an extreme outlier.
All p-values are two-sided and p  0.05 was considered signif-
icant. Statistical analyses were performed by the software package
Statistical Analysis Software (SAS) (version 9.3; SAS Institute Inc.,
Cary, NC, USA), and the software package Statistical Package for the
Social Sciences (SPSS) (SPSS 17.0, Chicago, IL, USA) was used for
graphics.
Results
Demographic data
In Table 1, the non-statin patients and simvastatin patients are
compared. The two groups are well comparable in age, aneurysm
diameter, co-morbidities and risk factors. The median aneurysm
diameter was 55 mm (48e120) for the non-statin and 55 mm
(48e120) for the simvastatin patients. The level of total cholesterol
and low-density lipoprotein (LDL) cholesterol was lower (p ¼ 0.017
and 0.057, respectively) in the simvastatin group. C-reactive protein
(CRP) level, ﬁbrinogen, creatinine and leukocyte count did not
differ among the two groups.
The inﬂuence of simvastatin on tissue oxidative stress and
antioxidant status in AAA
The inﬂuence of simvastatin on oxidative stress parameters and
tissue antioxidant status is shown in Table 2. In the simvastatin
patients, lipid peroxidation level, expressed as the 4-HNE concen-
tration, was signiﬁcantly lower (p¼ 0.012) compared with the non-
statin patients. H2O2 level was comparable in both groups
(p ¼ 0.832).
The simvastatin patients had increased activity of CAT
(p ¼ 0.023), but not SOD activity in AAA wall samples (p ¼ 0.650).The inﬂuence of simvastatin on TNF-a concentration and NF-kB
pathway activation
TNF-a concentration in AAA samples of simvastatin patients was
signiﬁcantly decreased compared to non-statin patients (p¼ 0.026)
as indicated in Table 2.
In Fig. 1(A), the densitometric analysis comparing 12 non-statin
and 12 simvastatin patients is shown (1:1 case to control). The ratio
of the phosphorylated p65 form over the total form of p65 was
signiﬁcantly lower (p ¼ 0.018) compared to the non-statin patients.
Fig. 1(B) shows a representative Western blot including three
simvastatin and three non-statin patients.Discussion
Prospective clinical studies investigating the effect of simvas-
tatin on AAA are challenging to conduct, because statins and acetyl
salicylic acid represent standard therapy for concomitant athero-
sclerosis.17 However, it has been increasingly appreciated that
statins may interfere with signalling pathways involved in AAA.
Figure 1. Simvastatin treatment counteracts NF-kB activation in abdominal aortic
aneurysmwall samples. (A) Densitometrical quantiﬁcation of p65 shown as the ratio of
the phosphorylated form over the total form of the protein (n ¼ 12 in the non-statin
and n ¼ 12 in the simvastatin group, 1:1 caseecontrol). (B) Representative Western
blot.
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tatin treatment inﬂuences oxidative stress and NF-kB p65 subunit
levels in human AAA-tissue.
AAA tissue is characterised by enhanced inﬁltration of macro-
phages and lymphocytes, which are a source of ROS such as
superoxide anion (O2
), H2O2 and nitric oxide.18 In our present
study, the general level of ROS, indicated by lipid peroxidation, in
the aneurysm tissue was markedly upregulated in the non-statin
group. This effect was reversed by simvastatin. This is in line with
Yoon et al.,19 who evidenced that simvastatin, in a dose-dependent
manner, decreases intracellular ROS formation in vascular smooth
muscle cells. In addition, some studies performed on rabbits with
atherosclerosis have suggested that simvastatin and atorvastatin
could act as an antioxidant and inhibit oxidation of LDL by activated
monocytes-derived macrophages.20,21
In our work, simvastatin signiﬁcantly increased CAT activity, but
had no effect on H2O2 concentration and SOD activity. In cells, H2O2
is generated from O2
 in a reaction catalysed by SOD. Therefore, no
increase in SOD activity may be a possible explanation for the
unchanged H2O2 level in our study. Moreover, changes in CAT levels
without alteration in SOD concentration were observed previ-
ously.22 Wassmann et al.20 showed that atorvastatin upregulates
CAT activity in vitro and in vivo, whereas it elicits no inﬂuence on
the expression of SOD and glutathione peroxidase.
To date, little is known about the inﬂuence of statins on H2O2
generation in aortic tissue, mainly since H2O2 has been employed as
ROSgenerator in experimentalmodels investigating the antioxidant
role of statins.23 We, thus, speculate that in our study an increase in
CATactivitywas not accompanied byH2O2 depletion due to the high
heterogeneity of AAA tissue, as well as a randomised localisation of
inﬂammatory cells which are the main source of H2O2. It is thought
that statins may increase CAT activity by activating Akt signalling
pathway.23 However, the exact molecular mechanisms by which
statins inﬂuence the CAT activity remain to be investigated.
Several studies have shown that circulating and tissue levels of
TNF-a were increased in patients with AAA, when compared withindividualswithoutAAA.24,25 Furthermore, in themouseAAAmodels,
the blockadeof TNF-a attenuated aneurysmformation.26 Inour study,
simvastatin treatment signiﬁcantly decreased TNF-a concentration in
human AAA tissue. This may be attributed to the anti-inﬂammatory
action of statins. Simvastatin has recently been shown to decrease
monocyte secretion of TNF-a, IL-6 and IL-1b in patients with hyper-
cholesterolaemia.27 Simvastatin also decreased TNF-a, IL-6 and
inhibited NF-kB in a rat model of cardiopulmonary bypass.28
Oxidative stress in the healthy vascular wall leads to a profound
activation of the NF-kB pathway29 and a strong activation of NF-kB
characterises aneurysmal tissue.30 A series of animal studies have
demonstrated that NF-kB inhibition may result in the prevention of
experimental AAA suggesting that NF-kB may be a key transcrip-
tion factor in aneurysm formation.31,32 Moreover, NF-kB signalling
pathway activation leads to MMP-2 and MMP-9 gene over-
expression and destruction of elastic ﬁbres in aortic tissue.31 So far,
only in vitro33 or animal13 studies have shown that either super-
oxide anion or H2O2-induced NF-kB activation can be suppressed
by simvastatin. Our study shows that in human AAA segments
excessive free radicals concentration is accompanied by NF-kB
activation and that simvastatin patients exhibit lower NF-kB p65
subunit levels. Therefore, the mechanism by which simvastatin
decreases TNF-a concentration appears to involve NF-kB activation
in human AAA wall tissue segments.
Albeit the roleof statinsas a lipid-loweringdrug isnot questioned,
there is a conﬂicting body of evidence regarding the use of statins as
standard therapy in the treatment of aneurysm patients. The most
recent study published by Karrowni et al.34 indicated a decreased
small AAA growth rate in patients receiving statins. Similar results
were obtained by Takagi et al.35 Nevertheless, a recent large growth
rate follow-up studyshowednocorrelationbetween simvastatin and
low AAA progression.34 Hurks et al.16 similarly found no convincing
evidence foruseofdifferent statins in causing signiﬁcantdecreases in
the levels of proteases or inﬂammatory compounds.
Our present work demonstrates that simvastatin exerts pleio-
tropic effects in human AAA tissue and that it has profound impact
on the free radical formation in aortic aneurysms. We further
propose that NF-kB plays an important role in this signalling
cascade.
Limitations of the study
Although our study indicates a plausible positive role of sim-
vastatin on oxidative stress and NF-kB signalling pathway in human
AAA wall tissue, it has several limitations. First, the study was
conducted on a relatively small group of patients. Therefore, to
diminish the risk of false positive results, a 2:1 case:control study
was performed. Second, 70% of samples used in our study are
obtained from active smokers, whose levels of free oxygen species
are higher compared to non-smokers, mainly through the activa-
tion of inﬂammatory cells. Smokers are more likely to have AAA
than non-smokers.36 However, considering that in both the non-
statin and simvastatin group the level of nicotine users were
similar, we can justify our assumption that the effect of nicotine had
only low signiﬁcance. Third, the spectroscopic and immunoenzy-
matic methods of detecting oxidative stress markers in AAA
samples are less sensitive than determination of proinﬂammatory
gene expression in endothelium, media and adventitia, though
further investigations are necessary to conﬁrm the role of simvas-
tatin on oxidative stress markers in AAA segments.
Conclusion
Our study shows that simvastatin treatment reduces NF-kB
activation and decreases TNF-a concentration in human AAA wall
A. Piechota-Polanczyk et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 133e137 137tissue, compared to non-statin patients. Moreover, simvastatin
increases CAT level and inhibits lipid peroxidation. Therefore,
pharmacological strategies targeting these generic components in
AAA may be effective in stopping the course of aortic aneurysm
disease.
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